Logo image of KZR

KEZAR LIFE SCIENCES INC (KZR) Stock Overview

USA - NASDAQ:KZR - US49372L2097 - Common Stock

4.22 USD
-0.18 (-4.09%)
Last: 10/10/2025, 8:40:18 PM
4.22 USD
0 (0%)
After Hours: 10/10/2025, 8:40:18 PM

KZR Key Statistics, Chart & Performance

Key Statistics
52 Week High8.95
52 Week Low3.53
Market Cap30.89M
Shares7.32M
Float6.36M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-9.69
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO06-21 2018-06-21
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KZR short term performance overview.The bars show the price performance of KZR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15

KZR long term performance overview.The bars show the price performance of KZR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of KZR is 4.22 USD. In the past month the price increased by 6.84%. In the past year, price decreased by -50.21%.

KEZAR LIFE SCIENCES INC / KZR Daily stock chart

KZR Latest News, Press Relases and Analysis

KZR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.77 407.19B
AMGN AMGEN INC 13.3 156.19B
GILD GILEAD SCIENCES INC 15.14 145.40B
VRTX VERTEX PHARMACEUTICALS INC 24.07 104.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.36B
REGN REGENERON PHARMACEUTICALS 12.37 59.85B
ARGX ARGENX SE - ADR 85.97 48.77B
ONC BEONE MEDICINES LTD-ADR 5.17 35.16B
INSM INSMED INC N/A 34.31B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 23.23B
BIIB BIOGEN INC 9.15 21.49B

About KZR

Company Profile

KZR logo image Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

Company Info

KEZAR LIFE SCIENCES INC

4000 Shoreline Ct Ste 300

South San Francisco CALIFORNIA 94080 US

CEO: John Fowler

Employees: 55

KZR Company Website

KZR Investor Relations

Phone: 16508225600

KEZAR LIFE SCIENCES INC / KZR FAQ

What is the stock price of KEZAR LIFE SCIENCES INC today?

The current stock price of KZR is 4.22 USD. The price decreased by -4.09% in the last trading session.


What is the ticker symbol for KEZAR LIFE SCIENCES INC stock?

The exchange symbol of KEZAR LIFE SCIENCES INC is KZR and it is listed on the Nasdaq exchange.


On which exchange is KZR stock listed?

KZR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KEZAR LIFE SCIENCES INC stock?

10 analysts have analysed KZR and the average price target is 12.75 USD. This implies a price increase of 202.13% is expected in the next year compared to the current price of 4.22. Check the KEZAR LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KEZAR LIFE SCIENCES INC worth?

KEZAR LIFE SCIENCES INC (KZR) has a market capitalization of 30.89M USD. This makes KZR a Nano Cap stock.


How many employees does KEZAR LIFE SCIENCES INC have?

KEZAR LIFE SCIENCES INC (KZR) currently has 55 employees.


What are the support and resistance levels for KEZAR LIFE SCIENCES INC (KZR) stock?

KEZAR LIFE SCIENCES INC (KZR) has a support level at 4.06 and a resistance level at 4.75. Check the full technical report for a detailed analysis of KZR support and resistance levels.


Should I buy KEZAR LIFE SCIENCES INC (KZR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KEZAR LIFE SCIENCES INC (KZR) stock pay dividends?

KZR does not pay a dividend.


When does KEZAR LIFE SCIENCES INC (KZR) report earnings?

KEZAR LIFE SCIENCES INC (KZR) will report earnings on 2025-11-10, after the market close.


What is the Price/Earnings (PE) ratio of KEZAR LIFE SCIENCES INC (KZR)?

KEZAR LIFE SCIENCES INC (KZR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.69).


What is the Short Interest ratio of KEZAR LIFE SCIENCES INC (KZR) stock?

The outstanding short interest for KEZAR LIFE SCIENCES INC (KZR) is 11.98% of its float. Check the ownership tab for more information on the KZR short interest.


KZR Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to KZR. When comparing the yearly performance of all stocks, KZR is a bad performer in the overall market: 91.36% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

KZR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to KZR. KZR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KZR Financial Highlights

Over the last trailing twelve months KZR reported a non-GAAP Earnings per Share(EPS) of -9.69. The EPS decreased by -50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.88%
ROE -71.62%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%30.74%
Sales Q2Q%N/A
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)-100%

KZR Forecast & Estimates

10 analysts have analysed KZR and the average price target is 12.75 USD. This implies a price increase of 202.13% is expected in the next year compared to the current price of 4.22.


Analysts
Analysts78
Price Target12.75 (202.13%)
EPS Next Y24.09%
Revenue Next YearN/A

KZR Ownership

Ownership
Inst Owners61.32%
Ins Owners2.15%
Short Float %11.98%
Short Ratio19.71